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Abstract: N-acetylglutamate synthase (NAGS) deficiency is a rare inborn error of 
metabolism affecting ammonia detoxification in the urea cycle. The product of NAGS is 
N-acetylglutamate which is the absolutely required allosteric activator of the first urea cycle 
enzyme carbamoylphosphate synthetase 1. In defects of NAGS, the urea cycle function can 
be severely affected resulting in fatal hyperammonemia in neonatal patients or at any later 
stage in life. NAGS deficiency can be treated with a structural analog of N-acetylglutamate, 
N-carbamyl-L-glutamate, which is available for enteral use as a licensed drug. Since NAGS 
deficiency is an extremely rare disorder, reports on the use of N-carbamyl-L-glutamate are 
mainly based on single patients. According to these, the drug is very effective in treating 
acute hyperammonemia by avoiding the need for detoxification during the acute metabolic 
decompensation. Also during long-term treatment, N-carbamyl-L-glutamate is effective in 
maintaining normal plasma ammonia levels and avoiding the need for additional drug therapy 
or protein-restricted diet. Open questions remain which concern the optimal dosage in acute 
and long-term use of N-carbamyl-L-glutamate and potential additional disorders in which the 
drug might also be effective in treating acute hyperammonemia. This review focuses on the role 
of N-carbamyl-L-glutamate for the treatment of acute hyperammonemia due to primary NAGS 
deficiency but will briefly discuss the current knowledge on the role of N-carbamyl-L-glutamate 
for treatment of secondary NAGS deficiencies.
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Introduction
Deficiency of N-acetylglutamate synthase (NAGS deficiency; NAGSD; #237310) 
belongs to the rare inborn errors of metabolism affecting the main pathway of ammonia 
detoxification, the urea cycle. The disorder leads to a deficiency of N-acetylglutamate 
(NAG), the product of NAGS (EC 2.3.1.1), which serves as the allosteric activator 
of the first enzyme of the urea cycle, carbamoylphosphate synthetase 1 (CPS1).1 
NAGSD can lead to neonatal onset life-threatening hyperammonemia2,3 but patients 
with a late presentation are also reported.4–6 The first patient suffering from NAGSD 
was described in 19812 and since then a small number of clinical reports have added 
further patients.4,5,7–16
Primary NAGSD is caused by mutations in NAGS,9 a gene located on 17q21.31 
which was described some years ago.10,17,18
In addition, deficiency of NAGS can also be secondary to inhibition of the enzyme 
by toxic metabolites or caused by lack of substrates. Inhibition of NAGS is assumed 
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Figure 1 Chemical structures of N-acetylglutamate and N-carbamyl-L-glutamate.
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to occur in some organic acidopathies19–23 or in valproate-
induced hyperammonemia.24
As soon as the diagnosis is suspected, patients with 
primary NAGSD should be treated with carglumic acid 
(synonymous: carbamylglutamate, CG, N-carbamyl-L-
glutamate; systematic name: (2S)-2-(carbamoylamino)
pentanedioic acid), which has been a licensed drug in Europe 
since 2003 and in the US since 2010 (Carbaglu®, Orphan 
Europe, Paris, France).25–27 Most patients with primary 
NAGSD who take CG do not need additional drugs or 
protein restriction in their diet, unless during acute illness 
or metabolic decompensation.
Patients with secondary NAGSD can be affected by 
acute hyperammonemia to the same extent as in primary 
NAGSD and might therefore benefit from treatment with 
CG.  However, hyperammonemia caused by defects outside 
the urea cycle is often multifactorial and only in part due to 
 secondary NAGSD. Accordingly, use of CG for  indications 
other than primary NAGSD needs several additional 
considerations and should be discussed separately.
This review will focus on the role of CG for the  treatment 
of acute hyperammonemia due to primary NAGSD. In 
addition, the current knowledge on the role of CG for 
 treatment of secondary NAGSD will be briefly presented 
and discussed.
Pharmacology and properties  
of carbamylglutamate
CG is a structural analog of human NAG (Figure 1) that can 
enter mitochondria to reach CPS1 which is only expressed 
intramitochondrially. Experiments in rats, both in vivo and 
in vitro, showed that CG activates the hepatic CPS1.25,28 
This was concluded based on a decrease of ammonia and 
an increase of urea concentrations in the blood, respectively, 
as well as an increase in CPS1 activity in the liver. NAG 
or CG is absolutely required for the urea cycle function. 
However, while CG is very effective in activating CPS1, it 
does not regulate the urea cycle function. In this respect, 
CG is  different from NAG which can regulate the urea cycle 
and which varies in concentration depending on the protein 
content of the diet, as does the NAGS activity.3
CG has been known as a chemical agent and was used 
as an unlicensed drug for many years. After becoming a 
licensed drug, Carbaglu® is available as tablets for oral/
enteral use only. If dissolved in water, the solution has an 
acidic taste. While human NAG is degraded in the cyto-
sol by amino acylase, CG is not subject to intracellular 
degradation.
The pharmacokinetic characteristics were investigated in 
12 healthy male probands who each received 100 mg CG per 
kg bodyweight (bw). The highest plasma concentrations of 
2.6 µg/mL (mean, range 1.8–4.8) were observed at 3 hours 
(median, range 2–4) after intake with a half-life elimination 
time of 5.6 hours (mean, range 4.3–9.5). Rate of resorption 
was about 30% while 5%–9% of CG was unchanged excreted 
in urine. Within 12 hours after intake, about 70% of CG is 
lost through urine or feces but small amounts of CG can still 
be found after 96 hours.
Indication, dosing,  
and contraindications
Currently, Carbaglu® is registered for use in patients with 
primary NAGSD both as adjunctive therapy in acute 
 hyperammonemia and during long-term treatment.
Carbaglu® is available as 200 mg tablets for enteral use 
only and should be administered after solution in water 
(minimum of 5–10 mL per 200 mg tablet) either orally or 
through a nasogastric or gastrostomy tube.
Treatment with CG may be started already on the first 
day of life. The recommended daily initial dose is 100 mg/kg 
bw, and this can be increased to 250 mg/kg bw if necessary. 
The dose during long-term treatment should be adjusted to 
maintain normal ammonia levels for age. The long-term 
daily maintenance dose can be as low as 10–15 mg/kg 
bw.29–30 In patients $25 kg bw, the recommended daily dose 
is 2.2 g/m2.
The daily dose should be divided in 3–4 doses based on 
a T
½
 = 5–6 hours which is substantially longer than T
½
 of the 
physiological analog NAG. The intake of CG is recommended 
immediately before a meal.
Contraindications refer to hypersensitivity to the active 
substance or to any of the excipients; in addition, use of CG is 
not recommended during pregnancy based on lack of human 
data and contraindicated during breast-feeding based on its 
presence in the milk of lactating rats.
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Adverse events
In the first NAGSD patient treated with CG, symptoms of 
intoxication occurred when the daily CG dose was  gradually 
increased to 750 mg/kg bw.25 This so called “Chinese 
restaurant syndrome”, characterized as a sympathomimetic 
reaction including tachycardia, profuse sweating, increased 
bronchial secretion and temperature, and persistent crying,25 
was probably due to the large dose given and was never 
described in any other patient. CG seems to be extremely 
well tolerated since almost no side-effects are reported. 
During the post-marketing surveillance, some adverse 
events did occur which were mostly not related to use of 
CG. According to the retrospective case series experience of 
the manufacturer on 23 patients treated over up to 20 years 
only 2 CG-related adverse events, namely bitter taste and 
hyperhydrosis, occurred.31
Methods
A literature search using MEDLINE® was performed using 
“n-acetylglutamate”, “hyperammonemia”, and “NAG 
synthase” as search terms. All papers were included that 
addressed the subject of this article including case reports 
and expert opinions.
Results and discussion
The MEDLINE® search identified a total of 50 articles from 
1972 to 2011. Of these, 25 were included in the analysis 
and the rest excluded because of lack of applicability for the 
 purpose of this review. In detail, 1 controlled  experimental 
study, 1 case series, 1 expert opinion, 3 animal studies, 
and 19 case reports were evaluated. Unfortunately, no 
randomized studies have investigated the use of CG which 
is probably due to the rarity of the disease.
Most papers identified are case reports. These date back 
to 1981 when CG was first administered to a human NAGSD 
patient.2,25 Since then, various case reports have been pub-
lished demonstrating the efficacy of CG treatment for acute 
and chronic management of NAGSD but with variable mor-
bidity and mortality mostly depending on the clinical course 
prior to CG administration.4,5,7,8,10,11,14,15,26,27,32 Most authors 
used a different protocol for initiation and maintenance 
of CG treatment resulting in varying doses applied. Doses 
for initiation of treatment during acute hyperammonemia 
ranged in most reports from 100 to 250 mg/kg bw per day 
divided in 4 doses. Maintenance daily doses ranged from 
15 to 150 mg/kg bw in most reports. In almost all instances, 
CG was given at least 3 times a day in accordance with 
the pharmacological properties and the need to mimic the 
physiological situation of a constant NAG availability. When 
the acute hyperammonemic phase was under control, dose 
of CG was reduced to the least effective daily dose which 
was reported to be as low as 15 mg/kg bw.29,30
In addition to the majority of NAGSD patients who 
presented as neonates, some patients with late-onset are 
described, in whom CG was successfully used to achieve 
a stable metabolic situation.6,30,33 In another patient with 
late-onset NAGSD, CG improved ammonia control but did 
not allow normalization of protein intake.16 To evaluate the 
effect of CG on urea production, a late-onset patient and her 
mother were investigated by in vivo stable isotope studies.4,33 
These showed a markedly reduced urea production at baseline 
which was increased more than 10-fold following treatment 
with CG. This effect was consistent with complete restoration 
of ureagenesis.
There are only 2 reports on the long-term outcome 
in patients with NAGSD.12,29 The first described a 9-year 
follow-up in a patient with moderate psychomotor retardation 
who was on a liberal diet prescription but eventually died 
from deep coma at the age of 9.5 years.12 The outcome was 
more favorable in another patient who was treated from 
3 months after birth and who remained neurologically normal 
at the age of 13 years.29 Besides, long-term data are available 
from 23 patients with NAGSD who were under treatment 
with CG for 7 to 249 months. Patients were treated with a 
mean initial daily dose of CG of 172 mg/kg bw and with a 
mean daily maintenance dose of 31 mg/kg bw. In this cohort, 
plasma ammonia and glutamine normalized quickly after 
start of therapy and remained within normal limits during 
the maintenance therapy, respectively. The neurological and 
psychomotor outcome was good since no patient deteriorated 
compared with the status at baseline.31
Probably the most convincing data concerning the effect 
of CG were reported in controlled experimental studies 
addressing the rate of ureagenesis as measured by isotope 
investigations in humans.21,34 These studies demonstrated 
that CG markedly enhances the rate of urea production in 
control subjects (n = 17), and normalized urea production in 
2 patients with NAGSD and propionic acidemia, respectively. 
However, whether this increase in ureagenesis does result in 
decreased ammonia toxicity resulting in an improved patient 
outcome must be studied further. At least, the results from 
isotope studies are not influenced by the often unknown and 
unpredictable additional factors which were likely present 
during the use of CG in many of the above case reports.
Costs of treatment with CG have been the subject of 
debate since licensing as an orphan drug led to a marked 
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Table 1 Disorders for which CG has been described
Disorders Patients number; age Outcome Reference
CPS1 deficiency 1; 3 years Normalization of plasma ammonia and glutamine 40
Hyperinsulinism/hyperammonemia syndrome 1; 5 years Moderate decrease of plasma ammonia 41
Methylmalonic acidemia 1; neonatal enhanced lowering of plasma ammonia 22
Propionic acidemia 2; neonatal enhanced lowering of plasma ammonia 42
Propionic acidemia 2; neonatal Dramatic fall in plasma ammonia with CG dose  
250 mg/kg; no response with CG dose 25 mg/kg
19
Propionic acidemia 1; 6 years increased urea production, but not normalized 21
Maple syrup urine disease 1; 4 years Significant decrease of plasma ammonia 43
Propionic acidemia 2; neonatal enhanced lowering of plasma ammonia 20
Propionic acidemia 7; 15 months to 13 years Decrease in plasma ammonia and glutamine 39
Methylmalonic acidemia, Propionic acidemia each 1; neonatal Rapid normalization of plasma ammonia 44
Propionic acidemia 4; neonatal effective in controlling hyperammonemia but no  
change of disease course; 3 of the 4 patients died
45
isovaleric acidemia 1; neonatal Rapid normalization of plasma ammonia 23
Abbreviations: CG, carglumic acid; CPS1, carbamoylphosphate synthetase 1.
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increase of the price compared with the unlicensed  product. 
There are concerns that patients risk being denied full 
treatment as a result of the high costs.35
Animal studies
Rats given a lethal dose of ammonium acetate could be 
 rescued by CG alone in 61% of the animals and in 100% if 
CG was given in combination with L-arginine.28 Similarly, 
CG administered to Wistar rats and Swiss albino mice led 
to an increase of blood urea accompanied by a decrease 
in blood ammonia.36 These results suggested the use in 
patients with NAGSD and with partial CPS1 deficiency. In 
another study, Wistar rats fed a protein-free diet developed 
hyperammonemia which could be effectively treated with 
CG.37 This led to the suggestion that CG could be useful to 
restore NAG levels in more common disorders such as in 
liver cirrhosis.
Further indications
The use of CG has been suggested as a diagnostic tool in 
neonatal patients with hyperammonemia both for acute 
management and for identifying the underlying disorder.38 
In a prospective study, 8 patients with a suspected urea 
cycle defect based on severe neonatal hyperammonemia and 
after exclusion of organic acidurias and fatty acid oxidation 
defects were subjected to oral CG treatment with a single 
initial dose of 114 to 200 mg/kg bw.38 In patients with later 
confirmed NAGSD, ammonia levels normalized within 
8 hours.  However, it is important to note that probably not 
all patients with NAGSD can be detected by a trial with 
CG during the acute hyperammonemic decompensation. 
One example was reported, when hyperammonemia did 
not resolve over 15 hours in a patient with severe neonatal 
onset of later confirmed NAGSD.15 Thus, use of CG must 
not delay initiation of other treatment modalities, such as 
intravenous sodium benzoate, sodium phenylacetate, and 
extracorporeal ammonia detoxification especially in cases 
in which the diagnosis is not yet established. Whether use 
of CG should be continued in case of initial unresponsive-
ness must be decided on an individual basis depending on 
all circumstances.
In addition to the use of CG in primary NAGSD, the 
use of CG for treatment of acute hyperammonemia was 
reported in a few other disorders and was also discussed 
based on isotope studies in healthy volunteers.34 Recently, 
the first prospective clinical trial in pediatric patients with 
propionic acidemia presented evidence of the benefit of CG 
on plasma ammonia and ureagenesis.39 Lately, the indications 
of  Carbaglu® were extended to the use in hyperammonemia 
due to isovaleric acidemia, methymalonic acidemia, and 
propionic acidemia.
While the papers listed in Table 1 report on the successful 
use of CG, there might well be a bias due to under-reporting 
of ineffective interventions. For instance, the author of this 
review has given CG to a patient with isovaleric acidemia 
during severe neonatal decompensation but without any 
effect on ammonia levels. Moreover, it should be noted 
that most papers listed in Table 1 are single case reports 
and their findings should be further verified in controlled 
 studies. Unlike with primary NAGSD, this research should 
be feasible in the group of organic acidemias given their 
higher prevalence. Obviously, the best way to achieve this 
would be in an international multi-center approach including 
centers from Europe and the US.
In a recent paper, the pathophysiology of valproate-
 induced hyperammonemia was investigated.24 It has long 
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been speculated that valproate leads to a direct inhibition 
of NAGS. In an elegant study, NAGS inhibition was dem-
onstrated to be due to accumulation of valproyl-CoA, a 
valproate metabolite. According to this finding, use of CG in 
valproate-induced hyperammonemia has a rationale.
Conclusion
The role of CG in the treatment of acute hyperammonemia 
due to N-acetylglutamate synthase deficiency is very clear 
and supported by evidence from scientific work, animal 
 studies, and mostly clinical case reports. Open questions 
remain concerning the dose required during the initiation 
of therapy and during long-term therapy. Also, whether 
adjunctive drug therapy or protein-restricted diet is required 
needs to be defined in more detail, although it seems that CG 
can be the sole treatment for NAGSD. The role of CG for 
other disorders such as organic acidemias is less clear despite 
increasing evidence from case reports and isotope studies 
supporting the beneficial effect in acute hyperammonemia.
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